



UNIVERSITY OF LEEDS

This is a repository copy of *MicroRNA-21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/128915/>

Version: Accepted Version

---

**Article:**

Alshanwani, AR, Riches-Suman, K, O'Regan, DJ et al. (3 more authors) (2018)  
MicroRNA-21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells. *IUBMB Life*, 70 (7). pp. 649-657. ISSN 1521-6543

<https://doi.org/10.1002/iub.1751>

---

© 2018 International Union of Biochemistry and Molecular Biology. This is the peer reviewed version of the following article: Alshanwani, A. R., Riches-Suman, K., O'Regan, D. J., Wood, I. C., Turner, N. A. and Porter, K. E. (2018), MicroRNA-21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells. *IUBMB Life*, 70: 649-657., which has been published in final form at <https://doi.org/10.1002/iub.1751>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



**MicroRNA-21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells**

|                               |   |
|-------------------------------|---|
| Journal:                      | <i>IUBMB Life</i>   |
| Manuscript ID                 | Draft   |
| Wiley - Manuscript type:      | Research Communication  |
| Date Submitted by the Author: | n/a   |
| Complete List of Authors:     | Alshanwani, Aliah; University of Leeds, LICAMM<br>Riches, Kirsten; University of Bradford School of Medical Sciences<br>O'Regan, David; Leeds General Infirmary, Department of Cardiac Surgery<br>Wood, Ian; University of Leeds, Biomedical Sciences<br>Turner, Neil; University of Leeds, Cardiovascular Medicine<br>Porter, Karen; University of Leeds, LICAMM |
| Keywords:                     | disease models, human molecular disease, MAPK (mitogen-activated protein kinases), PI3-kinase, signal transduction  |
|                               |   |

SCHOLARONE™  
Manuscripts

Only

1  
2  
3  
4 **MicroRNA-21 drives the switch to a synthetic phenotype in human**  
5  
6 **saphenous vein smooth muscle cells**  
7  
8  
9

10 Aliah R. Alshanwani<sup>1,2</sup>. Kirsten Riches-Suman<sup>1,3</sup>. David J. O'Regan<sup>2,4</sup>. Ian C. Wood<sup>5</sup>.  
11  
12 Neil A. Turner<sup>1,2</sup>. Karen E. Porter<sup>1,2</sup>.  
13  
14

15  
16 <sup>1</sup>Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular  
17 and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK, LS2 9JT.  
18  
19

20  
21 <sup>2</sup>Multidisciplinary Cardiovascular Research Centre (MCRC), University of Leeds, Leeds,  
22 UK, LS2 9JT.  
23  
24

25  
26  
27 <sup>3</sup>School of Chemistry and Biosciences, University of Bradford, Bradford, UK, BD7 1DP.  
28  
29

30  
31 <sup>4</sup>Department of Cardiac Surgery, The Yorkshire Heart Centre, Leeds General Infirmary,  
32 Leeds, UK, LS1 3EX.  
33  
34

35  
36 <sup>5</sup>School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds,  
37 Leeds, UK, LS2 9JT.  
38  
39  
40

41  
42 **Corresponding Author:**  
43  
44

45 Karen E Porter. Division of Cardiovascular and Diabetes Research, LICAMM,  
46 University of Leeds, Leeds, UK, LS2 9JT. Tel: 0113 3434806. Fax: 0113 3434803.  
47  
48

49 Email: [k.e.porter@leeds.ac.uk](mailto:k.e.porter@leeds.ac.uk)  
50  
51

52  
53 **Running title: MicroRNA-21 modulates smooth muscle cell phenotype**  
54  
55  
56  
57  
58  
59  
60

## Abstract

Aims: Cardiovascular disease is a leading cause of morbidity and mortality. Smooth muscle cells (SMC) comprising the vascular wall can switch phenotypes from contractile to synthetic, which can promote the development of aberrant remodelling and intimal hyperplasia (IH). MicroRNA-21 (miR-21) is a short, non-coding RNA that has been implicated in cardiovascular diseases including proliferative vascular disease and ischaemic heart disease. However, its involvement in the complex development of atherosclerosis has yet to be ascertained.

Methods: Smooth muscle cells (SMC) were isolated from human saphenous veins (SV). miR-21 was over-expressed and the impact of this on morphology, proliferation, gene and protein expression related to synthetic SMC phenotypes monitored.

Results: Over-expression of miR-21 increased the spread cell area and proliferative capacity of SV-SMC and expression of MMP-1, whilst reducing RECK protein, indicating a switch to the synthetic phenotype. Furthermore, PDGF-BB (a growth factor implicated in vasculoproliferative conditions) was able to induce miR-21 expression via the PI3K and ERK signalling pathways.

Conclusion: This study has revealed a mechanism whereby PDGF-BB induces expression of miR-21 in SV-SMC, subsequently driving conversion to a synthetic SMC phenotype, propagating the development of IH. Thus, these signaling pathways may be attractive therapeutic targets to minimise progression of the disease.

**Keywords:**

MicroRNA-21, PDGF, saphenous vein, smooth muscle cell, phenotype, remodelling

**List of Abbreviations**

BIRC3, baculoviral IAP repeat containing 3; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVD, cardiovascular disease; EC, endothelial cell; ERK1/2, extracellular regulated kinase 1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IH, intimal hyperplasia; IL, interleukin; IL1R2, interleukin-1 receptor 2; IMA, internal mammary artery; ITGB2, integrin subunit beta 2; KDR, kinase insert domain receptor; MGM, minimal growth medium; miRs, microRNAs; MMP, matrix metalloproteinase; MT1-MMP, membrane type 1 matrix metalloproteinase; PCI, percutaneous coronary intervention; PDGF-BB, platelet-derived growth factor BB; PPARG, peroxisome proliferator-activator receptor gamma; RECK, reversion inducing cysteine rich protein with Kazal motifs; RQ, relative quantification; SMC, smooth muscle cell; SV, saphenous vein; VWF, von Willibrand factor.

## Introduction

Despite continued advances in knowledge and therapeutic strategies, atherosclerosis remains the leading cause of cardiovascular disease (CVD) around the world [1]. Atherosclerosis is a chronic, progressive inflammatory disorder which involves interactions of different vascular cell types that are the underlying cause of angina, coronary artery disease (CAD) and stroke [2]. Atherosclerosis in the coronary arteries can block the blood supply to the heart tissue, causing myocardial infarction and necessitating vascular reconstruction.

The advent of percutaneous coronary intervention (PCI) has improved treatment options for patients, yet coronary artery bypass grafting (CABG) remains the mainstay for patients with multivessel disease and impaired ejection fraction [3]. The commonly used bypass conduits for CABG are the autologous internal mammary artery (IMA) and the saphenous vein (SV), with the SV graft remaining popular for multiple grafts due to its ease of harvesting and ready availability. However, during the first year post-CABG up to 15% of SV grafts fail with an expected 4-5% attrition rate each year thereafter [4]. Therefore, in 10 years SV graft failure rates are close to 50% and approximately 31% of all CABG surgeries in the United Kingdom necessitate re-intervention [5]. Conversely, 80-95 % of IMA grafts remain patent at 10 years [6].

The underlying pathological lesion of SV graft stenosis is the characteristic development of intimal hyperplasia (IH). IH can be detected approximately 4-6 weeks following SV grafting [7] and this can be further augmented by continued atherosclerotic lesion development in the vein graft within one year following vein implantation [8].

1  
2  
3 Smooth muscle cells (SMC) constitute the major cell type in the blood vessel wall, and  
4 their principal role is to maintain vascular tone and vessel homeostasis. In health, SMC  
5 exist in a contractile, differentiated state with a low turnover rate, but following injury  
6 and in response to circulating cytokines and growth factors, they switch to a synthetic  
7 phenotype that is characterised by increased proliferation, loss of contractility, and  
8 secretion of extracellular matrix degrading enzymes. This encourages migration of SMC  
9 into the intimal layer of the blood vessel, thus initiating a remodelling event as an  
10 adaptive response that ultimately can exacerbate the development of intimal hyperplasia  
11 and restenosis [9].  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Platelet-derived growth factor BB (PDGF-BB) is a potent SMC mitogen and  
25 chemoattractant that induces cellular dedifferentiation into a synthetic phenotype,  
26 increasing proliferation and migration into the intima such as is evident in atherosclerosis  
27 and restenosis [10, 11]. In addition to being secreted from platelets, PDGF is secreted by  
28 endothelial cells (EC) and SMC [12]. PDGF-BB-induced SMC dedifferentiation is driven  
29 through the phosphoinositide-3-kinase/AKT and mitogen-activated protein kinase  
30 extracellular regulated kinase 1/2 (ERK1/2) intracellular transduction pathways [13]. As  
31 increased SMC migration and proliferation constitute the cornerstone of IH and SV graft  
32 failure, PDGF-BB is implicated in its progression [14].  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 MicroRNAs (miRs) are short, non-coding RNAs that negatively regulate gene  
47 expression. Emerging evidence reveals miR-21 to be one of the most dysregulated  
48 miRNAs in the cardiovascular system. miR-21 is expressed in most cardiovascular cell  
49 types including vascular SMC [15] and can mediate the pathological development of  
50 neointimal hyperplasia [15], atherosclerotic lesions [16], and cardiac hypertrophy and  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 fibrosis [17, 18]. Indeed, miR-21 expression is reportedly elevated in human  
4 atherosclerotic plaques [19] and, at least in murine models, is up-regulated and mediates  
5 neointimal formation following vein grafting [20].  
6  
7  
8  
9

10  
11 Despite advances in modern therapies, vein graft failure is still a significant problem that  
12 requires identification of novel targets for development of new therapeutics to ameliorate  
13 adverse vascular remodelling. Thus, the aim of this study was to explore a relationship  
14 between miR-21 and PDGF in the cellular mechanisms underlying SV-SMC dysfunction  
15 that occurs in vein graft failure.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Experimental procedures

### Cell culture

Human SV specimens were obtained from patients undergoing elective CABG surgery at the Leeds General Infirmary. Local ethical committee and informed, written patient consent was obtained and the study conformed to the Declaration of Helsinki. SV-SMC were cultured using an explant technique as previously described [21]. As we have previously demonstrated profound phenotypic changes in SV-SMC isolated from patients with Type 2 diabetes [22-24], all experiments were performed using cells cultured from patients without a diagnosis of diabetes, and used between passages 3 and 5.

### miR-21 transfection

Subconfluent SV-SMC were transfected with 30 nM premiR-21 (hsa-miR21-5p; AM17100) or its associated negative control (AM17110; “premiR-negative”) using Lipofectamine 2000 (all Life Technologies, Paisley, UK). Cells were harvested after 72 h and endpoints determined (cell morphology, F-actin staining, RNA isolation) or proliferation assays performed.

### Cell morphology

Images of sub-confluent cells were captured under the light microscope at x100 magnification. For each patient population, 50 randomly selected cells were measured by tracing the cell boundaries and areas were calculated using ImageJ software (<https://imagej.nih.gov/ij/>) [25]. For cytoskeletal assessment, cells were cultured on glass coverslips in medium containing 0.4% foetal calf serum (minimal growth medium,

1  
2  
3 MGM) for 72h. After fixation in 4% paraformaldehyde, F-actin fibres were labelled using  
4  
5 rhodamine phalloidin (1:40) as previously described [26]. Fluorescence images were  
6  
7 captured using an LSM510 upright confocal microscope at x200 magnification.  
8  
9

### 10 11 **Cell proliferation**

12  
13  
14 SV-SMC proliferation was determined by in vitro counting of live cells in triplicate using  
15  
16 trypan blue and a haemocytometer as we described previously [22].  
17  
18  
19

### 20 **Quantitative real-time RT-PCR**

21  
22  
23 For quantification of miR-21 expression, cellular RNA was used to produce cDNA using  
24  
25 TaqMan MicroRNA Reverse Transcription System. MiR-21 expression levels were  
26  
27 measured using miR-21 TaqMan microRNA assay (Applied Biosystems) and real-time  
28  
29 PCR performed according to manufacturer's protocols. Data were analysed using the  
30  
31 comparative CT method and values normalised to U6 expression. For gene expression  
32  
33 studies, cellular RNA was extracted and real-time RT-PCR was performed in triplicate  
34  
35 using Applied Biosystems 7500 PCR system and intron-spanning human matrix  
36  
37 metalloproteinase-1 (*MMP1*; Hs00233958\_m1), interleukin 1-alpha (*IL1α*;  
38  
39 Hs00174092\_m1), reversion inducing cysteine rich protein with Kazal motifs (*RECK*;  
40  
41 Hs01019179\_m1) primers and TaqMan® probes. Data are expressed as percentage of  
42  
43 glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) endogenous control levels  
44  
45 (Hs99999905\_m1) using the formula  $2^{-\Delta CT} \times 100$  or to a control sample using the formula  
46  
47  
48  
49  
50  
51  $2^{-\Delta\Delta CT}$ .  
52  
53

### 54 **Atherosclerosis microarray**

1  
2  
3 SV-SMC from four different patients were transfected with 30 nM premiR-21 or  
4 equivalent premiR negative control. Cellular RNA was extracted and reverse transcribed.  
5  
6  
7  
8 Expression levels of 84 atherosclerosis-related genes were quantified using a focused  
9  
10 SYBR green-based real-time PCR array (RT2 Profiler Human Atherosclerosis,  
11  
12 SABiosciences / Qiagen PAHS-038ZA-12) and the Applied Biosystems 7500 Real-time  
13  
14 PCR system.  $\Delta$ CT vales for the target genes were calculated by subtracting the mean CT  
15  
16 value (threshold cycle number) of the 5 housekeeping genes on the array from the CT  
17  
18 value of the target genes. Data are expressed as relative quantification (RQ) values  
19  
20 compared with the 5 housekeeping genes using the formula  $RQ=2^{-\Delta CT}$ .  
21  
22  
23

### 24 25 **Immunoblotting**

26  
27  
28 Immunoblotting was performed essentially as per our previous protocol [27]. Whole cell  
29  
30 homogenates were prepared and protein was separated using SDS-PAGE 10%  
31  
32 polyacrylamide gels and transferred to PVDF membranes. Phosphorylation of AKT and  
33  
34 ERK1/2 was determined by immunoblotting with phospho-specific monoclonal  
35  
36 antibodies (#9106 mouse, #4060 rabbit respectively). Membranes were re-probed with  
37  
38 AKT and ERK expression antibodies (#2920 and #4695 respectively, all Cell Signaling  
39  
40 Technology). For RECK protein, a 7.5% SDS-PAGE gel was prepared and  $\alpha$ -tubulin  
41  
42 used as a loading control.  
43  
44  
45  
46

### 47 48 **Statistical Analysis**

49  
50  
51 All results are expressed as a mean  $\pm$  SEM. Statistical analysis was performed using  
52  
53 GraphPad Prism 7 by one-way ANOVA followed by Newman-Keuls multiple  
54  
55 comparisons post-hoc test. Paired ratio *t*-tests were performed on log transforms of all  
56  
57  
58  
59

1  
2  
3 normalised data to test statistical significance where appropriate.  $P < 0.05$  was considered  
4  
5 statistically significant.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

## Results

### Over-expressing miR-21 induces phenotypic and functional changes in SV-SMC

Cells over-expressing miR-21 exhibited an enlarged, rhomboid morphology which was visible under phase contrast microscopy (Fig. 1A), accounting for a 1.7-fold increased spread area relative to control premiR-negative transfected cells (Fig. 1B). This enlarged morphology was further emphasised by rhodamine phalloidin fluorescence microscopy, which revealed that the F-actin cytoskeleton appeared visually intact in these morphologically aberrant SMC (Fig. 1C). Cells over-expressing miR-21 also exhibited increased cell proliferation, resulting in a 1.8-fold increase in cell number relative to control premiR-negative transfected cells after 4 days (Fig. 1D).

### Microarray identification of *MMP1* and *IL1A* as miR-21-regulated genes in SV-SMC

Using SMC over-expressing miR-21, we performed a focused microarray to explore expression of 84 potential target genes related to atherosclerosis and cardiovascular disease. The pattern of gene expression induced by miR-21 over-expression is presented in a volcano scatter plot (Fig. 2A). Of the 84 genes studied, 10 genes presented a fold change  $\geq \pm 1.5$ . *MMP1*, *MMP3*, interleukin 1 receptor 2 (*IL1R2*), peroxisome proliferator-activator receptor gamma (*PPARG*) and integrin subunit beta 2 (*ITGB2*) displayed  $\geq 1.5$ -fold increase in the premiR-21 transfected cells relative to control premiR-negative transfected SV-SMC. Conversely, interleukin-1 $\alpha$  (*IL1A*), kinase insert domain receptor (*KDR*), Baculoviral IAP repeat containing 3 (*BIRC3*), von Willibrand

1  
2  
3 factor (*VWF*) and interleukin 5 (*IL5*) showed > 1.5-fold decrease in the premiR-21  
4 transfected cells relative to premiR-negative controls (Table 1).  
5  
6

7  
8  
9 Genes identified by microarray were subsequently validated using specific TaqMan  
10 probes and RT-PCR using RNA from six different patients, which included the four  
11 original samples that were analysed by array. In this series of experiments, we confirmed  
12 a statistically significant increase in *MMP1* mRNA expression in the premiR-21  
13 transfected cells versus premiR-negative controls (Fig. 2B). On the contrary, we were  
14 unable to validate the *IL1A* data where only a small but non-significant reduction was  
15 evident in the premiR-21 transfected cells relative to the control SV-SMC (Fig. 2C).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **miR-21 over-expression downregulates RECK in SV-SMC**

27

28  
29 RECK is a recognised target of miR-21 that is known to be involved in cell proliferation  
30 [28]. In our study, miR-21 over-expression in SV-SMC for 72h led to ~50% reduction in  
31 *RECK* mRNA expression levels (Fig. 2D), yet there were no detectable changes in RECK  
32 protein levels at this time point (data not shown). Extended study revealed a ~40%  
33 reduction in RECK protein levels in response to premiR-21 transfection after 8 days (Fig.  
34 2E,F).  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **PDGF-BB increases miR-21 expression via AKT and ERK1/2 pathways in SV-** 45 **SMC:** 46

47  
48  
49 To identify the potential source of miR-21 up-regulation in SV-SMC we treated cells  
50 with the potent chemoattractant and mitogen PDGF-BB which is known to be increased  
51 in proliferative vascular disorders [29]. Exposure of SV-SMC for 24 h to physiologically  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 relevant (1 ng/ml and 10 ng/ml; [30, 31]) concentrations of PDGF stimulated miR-21  
4 expression; an effect that was maintained up to 72 h (Fig. 3A).

5  
6  
7  
8 Binding of PDGF to its cognate receptor results in a signalling cascade that induces  
9 phosphorylation of both AKT and ERK1/2 [32]. To determine which of these pathways  
10 was involved in inducing miR-21 expression, we used specific pharmacological  
11 inhibitors. PDGF-BB treatment induced phosphorylation of both AKT and ERK1/2 as  
12 expected and pathway-specific phosphorylation events were inhibited by pre-treating  
13 with inhibitors of AKT (LY294002) and ERK1/2 (PD98059) pathways (Fig. 3B).  
14 Inhibiting either pathway independently was able to completely abrogate the induction of  
15 miR-21 expression by PDGF-BB, confirming the requirement for both pathways in miR-  
16 21 regulation in these cells (Fig. 3C).

### 30 **PDGF-BB mimics the effect of miR-21 over-expression on MMP-1 and RECK** 31 **expression**

32  
33  
34  
35  
36 Having shown that PDGF-BB increased miR-21 expression (Fig. 3), and that miR-21  
37 overexpression led to an increase in *MMP1* mRNA expression and inhibition of RECK  
38 expression (Fig. 2), we proceeded to seek evidence for a link between PDGF and these  
39 targets. PDGF-BB significantly induced *MMP1* mRNA at 24 h in a concentration-  
40 dependent manner, although this effect was transient and expression levels returned to  
41 baseline by 72 h (Fig. 3D). In parallel, *RECK* mRNA was significantly downregulated in  
42 a concentration-dependent manner, and this effect was maintained over the full 72 h  
43 period of study (Fig. 3E).

## Discussion

Dysregulation of SMC differentiation is an event critical to the development of CVD. The presence of characteristically dedifferentiated SMC in IH is well recognised and thus investigations into the mechanisms contributing to this phenotypic reversion are of significant clinical importance. Two of the predominant mechanisms for SV graft failure are IH and accelerated atherosclerosis. In the present study, we utilised clinically relevant human SV-SMC and revealed signalling pathways whereby overexpression of miR-21 led to acquisition of a synthetic phenotype.

### miR-21 as a driver of synthetic SMC phenotypes

The importance of miR-21 in the cardiovascular system is well recognised. It is aberrantly expressed in vascular SMC [15] and EC [33] following vascular injury, and is significantly up-regulated in human atherosclerotic plaques [19], injured rat carotid arteries [15] and following vascular grafting in mice [20]. However, its influence on human SV-SMC remodelling following bypass grafting is unknown. In this study we used an over-expression approach to determine the impact of miR-21 on SMC phenotype and function *in vitro*.

Synthetic SMC in remodelling vessels are known to adopt a rhomboid morphology and have a high turnover rate [34]. Both of these features were observed in miR-21 over-expressing SV-SMC, confirming that miR-21 was a driver of this dedifferentiation. Given the widespread reporting of miR-21 as a proto-oncogene that increases proliferation in a number of pathological models including vascular SMC [15, 35, 36], its impact specifically on SV-SMC is perhaps unsurprising. In direct contrast however,

1  
2  
3 miR-21 has been purported to drive a differentiated, contractile phenotype in human  
4 pulmonary artery SMC [37] and correlates with expression of smooth muscle  
5 differentiation genes [38]. Given this disparity, we perceived it was important to validate  
6 this hypothesis in clinically relevant human SV-SMC. Our present data highlight the  
7 species- and cell type-specific nature of miR-21's mechanism of action.  
8  
9  
10  
11  
12  
13

### 14 15 **Identification of downstream miR-21 targets that contribute to vascular remodelling**

16  
17  
18 As miR-21 over-expressing cells were dedifferentiated, and such SMC are common in  
19 IH, we proceeded to use a microarray-based approach to identify downstream targets of  
20 miR-21 in SV-SMC that may contribute to the development of CVD. *IL1A* is a pro-  
21 inflammatory cytokine that is elevated in atherosclerosis [39], however its regulation by  
22 miR-21 could not be corroborated in SV-SMC. In contrast, the array data for *MMP1* was  
23 validated using specific Taqman assays which identified *MMP1* as being regulated by  
24 miR-21 in these cells.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 MMPs play an important role in degrading the ECM and can contribute to matrix  
37 destabilisation [40]. Furthermore, digestion of integrins by MMPs can facilitate SMC  
38 dedifferentiation [41]. Interestingly, in SV-SMC, there was a positive relationship  
39 between miR-21 and *MMP1* mRNA expression. Normally, miRs negatively regulate the  
40 expression of direct gene targets [42]. This suggests that the relationship between miR-21  
41 and *MMP1* in SV-SMCs is complex and involves an intermediary step whereby the target  
42 of miR-21 firstly inhibits expression of a gene that normally acts as a repressor of *MMP1*  
43 expression.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Transcriptional regulation of MMPs is complicated, encompassing multiple intracellular  
4 signalling pathways and transcription factors [43]. RECK is a membrane-bound MMP  
5 inhibitor that has been reported to regulate the gelatinases MMP-2 and -9, and their  
6 activator membrane type 1-MMP (MT1-MMP) [44]. Previous studies have shown that  
7 miR-21 overexpression in various cancer cell lines reduces mRNA and protein levels of  
8 RECK [45]. Furthermore, in vascular SMC, knockdown of RECK led to increased MMP-  
9 2 and -9 expression, and an increase in cell proliferation [46]. In the present study,  
10 transfection with premiR-21 inhibited *RECK* mRNA expression after 3 days, and RECK  
11 protein levels after 8 days. Evidence of a direct effect of RECK on MMP-1 expression  
12 remains elusive, thus the relationship in SV-SMC is worthy of further investigation.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **PDGF-BB is an important regulator of SMC function via miR-21**

28  
29  
30 On the basis of the above evidence, elevated miR-21 expression can cause vascular SMC  
31 dysfunction leading to dedifferentiation, enhanced proliferation and degradation of the  
32 ECM. MiR-21 is known to be elevated in proliferative SMC present in IH and  
33 atherosclerotic plaques, thus identifying the factor(s) responsible for this elevation is of  
34 clinical relevance.  
35  
36  
37  
38  
39  
40  
41  
42

43 PDGF-BB is a potent SMC chemoattractant and mitogen, which can promote SMC  
44 dedifferentiation and proliferation [10, 11] and is elevated following vascular injury and  
45 angioplasty [29]. PDGF-BB is purported to regulate miR-21 in a number of cell types,  
46 including rat aortic SMC [47]. Our observations of a modest yet consistent up-regulation  
47 of miR-21 by PDGF-BB in SV-SMC that persists over time aligns with this. However, a  
48 recent study raised the possibility of a more complex relationship whereby miR-21 could  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 prevent the mitogenic effects of PDGF [36]. Further experiments examining any  
4 attenuation of PDGF-BB signalling through over-expressing miR-21 may answer this  
5 question.  
6  
7  
8  
9

10 Both the PI3K/AKT and ERK1/2 pathways are activated upon binding of PDGF-BB to  
11 its receptor, leading to SMC dedifferentiation [13, 32]. In our study, inhibition of either  
12 pathway was sufficient to completely ablate miR-21 expression by PDGF-BB, indicating  
13 that both pathways are required. Interestingly, miR-21 itself can stimulate the AKT  
14 pathway (via suppression of PTEN; [15, 35]) and the ERK pathway [48] potentially  
15 causing a positive feedback loop that reinforces the effect of PDGF-BB on miR-21  
16 expression.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Treatment of SV-SMC with PDGF-BB was sufficient to increase expression of *MMP1*  
29 mRNA and reduce expression of RECK. Reports of a relationship between PDGF-BB  
30 and RECK in the literature are lacking, although one study demonstrated that loss of  
31 RECK in fibroblasts caused a disordered chemotactic response to PDGF [49]. To our  
32 knowledge, ours is the first report of PDGF-BB regulating RECK expression in human  
33 SMC via up-regulation of miR-21. The relationship between PDGF and MMP-1 is  
34 however, better recognised and previous studies have reported a positive relationship  
35 between PDGF and MMP-1 [50]. Our data concur with these findings, and further  
36 suggest a mechanism mediated via miR-21.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

During pathological vascular remodelling, secretion of cytokines and growth factors from multiple vascular cell types are increased. Here, we have demonstrated how one such growth factor, PDGF-BB, controls SV-SMC phenotype, at least in part, through miR-21. This has downstream effects on RECK and MMP-1 expression and leads to SV-SMC dedifferentiation (see Fig. 4 for summary diagram). Targeted inhibition of PDGF-BB signalling may be a beneficial therapeutic strategy following coronary artery bypass grafting to limit post-graft development of neointimal hyperplasia.

1  
2  
3 **Acknowledgements**  
4

5  
6 We are grateful to Philip Warburton for cell culture technical expertise.  
7

8  
9 **Financial support and sponsorship**  
10

11  
12 ARA was supported by a studentship from King Saud University, College of Medicine,  
13 Riyadh, Saudi Arabia.  
14  
15

16  
17 **Conflict of interests**  
18

19  
20 The authors declare no conflict of interest.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Libby P, Ridker PM, Hansson GK: **Progress and challenges in translating the biology of atherosclerosis.** *Nature* 2011, **473**(7347):317-325.
2. Libby P: **Inflammation in atherosclerosis.** *Nature* 2002, **420**(6917):868-874.
3. Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R: **Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.** *Nature reviews Cardiology* 2016, **13**(2):79-98.
4. Nwasokwa ON: **Coronary artery bypass graft disease.** *Annals of internal medicine* 1995, **123**(7):528-545.
5. Deb S, Cohen EA, Singh SK, Une D, Laupacis A, Fremes SE: **Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study).** *Journal of the American College of Cardiology* 2012, **60**(1):28-35.
6. Wilson JM: **Coronary Artery Bypass Surgery and Percutaneous Coronary Revascularization: Impact on Morbidity and Mortality in Patients with Coronary Artery Disease.** In: *Coronary Artery Disease.* edn. Edited by Willerson JT, Holmes Jr DR. London: Springer London; 2015: 683-726.
7. Dietrich H, Hu Y, Zou Y, Huemer U, Metzler B, Li C, Mayr M, Xu Q: **Rapid development of vein graft atheroma in ApoE-deficient mice.** *The American journal of pathology* 2000, **157**(2):659-669.
8. Wang XW, Zhao XJ, Xiang XY: **Gene therapy for vein graft failure.** *Journal of cardiac surgery* 2013, **28**(2):144-147.
9. Alexander MR, Owens GK: **Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease.** *Annual review of physiology* 2012, **74**:13-40.
10. Clunn GF, Refson JS, Lynn JS, Hughes AD: **Platelet-derived growth factor beta-receptors can both promote and inhibit chemotaxis in human vascular smooth muscle cells.** *Arteriosclerosis, thrombosis, and vascular biology* 1997, **17**(11):2622-2629.
11. Salabei JK, Hill BG: **Implications of autophagy for vascular smooth muscle cell function and plasticity.** *Free radical biology & medicine* 2013, **65**:693-703.
12. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW *et al*: **Inflammation, growth factors, and pulmonary vascular remodeling.** *Journal of the American College of Cardiology* 2009, **54**(1 Suppl):S10-19.
13. Gan J, Li P, Wang Z, Chen J, Liang X, Liu M, Xie W, Yin R, Huang F: **Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway.** *Experimental and therapeutic medicine* 2013, **6**(4):899-903.
14. Xu B, Luo Y, Liu Y, Li BY, Wang Y: **Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression.** *American journal of physiology Heart and circulatory physiology* 2015, **308**(9):H980-989.
15. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C: **MicroRNA expression signature and antisense-mediated depletion reveal an essential**

- 1  
2  
3 **role of MicroRNA in vascular neointimal lesion formation.** *Circulation*  
4 *research* 2007, **100**(11):1579-1588.
- 5 16. Zuo K, Li M, Zhang X, Lu C, Wang S, Zhi K, He B: **MiR-21 suppresses**  
6 **endothelial progenitor cell proliferation by activating the TGFbeta signaling**  
7 **pathway via downregulation of WWP1.** *International journal of clinical and*  
8 *experimental pathology* 2015, **8**(1):414-422.
- 9 17. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C: **MicroRNAs**  
10 **are aberrantly expressed in hypertrophic heart: do they play a role in**  
11 **cardiac hypertrophy?** *The American journal of pathology* 2007, **170**(6):1831-  
12 1840.
- 13 18. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S,  
14 Nuovo GJ, Sen CK: **MicroRNA expression in response to murine myocardial**  
15 **infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase**  
16 **and tensin homologue.** *Cardiovascular research* 2009, **82**(1):21-29.
- 17 19. Raitoharju E, Lyytikainen LP, Levula M, Oksala N, Mennander A, Tarkka M,  
18 Klopp N, Illig T, Kahonen M, Karhunen PJ *et al*: **miR-21, miR-210, miR-34a,**  
19 **and miR-146a/b are up-regulated in human atherosclerotic plaques in the**  
20 **Tampere Vascular Study.** *Atherosclerosis* 2011, **219**(1):211-217.
- 21 20. McDonald RA, White KM, Wu J, Cooley BC, Robertson KE, Halliday CA,  
22 McClure JD, Francis S, Lu R, Kennedy S *et al*: **miRNA-21 is dysregulated in**  
23 **response to vein grafting in multiple models and genetic ablation in mice**  
24 **attenuates neointima formation.** *European heart journal* 2013, **34**(22):1636-  
25 1643.
- 26 21. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ:  
27 **Simvastatin inhibits human saphenous vein neointima formation via**  
28 **inhibition of smooth muscle cell proliferation and migration.** *Journal of*  
29 *vascular surgery* 2002, **36**(1):150-157.
- 30 22. Madi HA, Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE: **Inherent**  
31 **differences in morphology, proliferation, and migration in saphenous vein**  
32 **smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients.**  
33 *American journal of physiology Cell physiology* 2009, **297**(5):C1307-1317.
- 34 23. Riches K, Alshanwani AR, Warburton P, O'Regan DJ, Ball SG, Wood IC, Turner  
35 NA, Porter KE: **Elevated expression levels of miR-143/5 in saphenous vein**  
36 **smooth muscle cells from patients with Type 2 diabetes drive persistent**  
37 **changes in phenotype and function.** *Journal of molecular and cellular*  
38 *cardiology* 2014, **74**:240-250.
- 39 24. Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE: **Type 2 diabetes**  
40 **impairs venous, but not arterial smooth muscle cell function: possible role of**  
41 **differential RhoA activity.** *Cardiovascular revascularization medicine :*  
42 *including molecular interventions* 2014, **15**(3):141-148.
- 43 25. Riches K, Angelini TG, Mudhar GS, Kaye J, Clark E, Bailey MA, Sohrabi S,  
44 Korossis S, Walker PG, Scott DJ *et al*: **Exploring smooth muscle phenotype**  
45 **and function in a bioreactor model of abdominal aortic aneurysm.** *Journal of*  
46 *translational medicine* 2013, **11**:208.
- 47 26. Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, Midgley L, O'Regan  
48 DJ, Wood IC, Ball SG, Porter KE: **Simvastatin inhibits TNFalpha-induced**  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 **invasion of human cardiac myofibroblasts via both MMP-9-dependent and -**  
5 **independent mechanisms.** *Journal of molecular and cellular cardiology* 2007,  
6 **43(2):168-176.**
- 7 27. Turner NA, Ball SG, Balmforth AJ: **The mechanism of angiotensin II-induced**  
8 **extracellular signal-regulated kinase-1/2 activation is independent of**  
9 **angiotensin AT(1A) receptor internalisation.** *Cellular signalling* 2001,  
10 **13(4):269-277.**
- 11 28. Xu LF, Wu ZP, Chen Y, Zhu QS, Hamidi S, Navab R: **MicroRNA-21 (miR-21)**  
12 **regulates cellular proliferation, invasion, migration, and apoptosis by**  
13 **targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City,**  
14 **China.** *PloS one* 2014, **9(8):e103698.**
- 15 29. Caplice NM, Aroney CN, Bett JH, Cameron J, Campbell JH, Hoffmann N,  
16 McEniery PT, West MJ: **Growth factors released into the coronary circulation**  
17 **after vascular injury promote proliferation of human vascular smooth**  
18 **muscle cells in culture.** *Journal of the American College of Cardiology* 1997,  
19 **29(7):1536-1541.**
- 20 30. Bruzelius M, Iglesias MJ, Hong MG, Sanchez-Rivera L, Gyorgy B, Souto JC,  
21 Franberg M, Fredolini C, Strawbridge RJ, Holmstrom M *et al*: **PDGFB, a new**  
22 **candidate plasma biomarker for venous thromboembolism: results from the**  
23 **VEREMA affinity proteomics study.** *Blood* 2016, **128(23):e59-e66.**
- 24 31. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G: **Cytokine levels in the**  
25 **serum of healthy subjects.** *Mediators of inflammation* 2013, **2013:434010.**
- 26 32. Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH: **Presenilins**  
27 **mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select**  
28 **signaling receptors. Selectivity of PS2 in platelet-derived growth factor**  
29 **signaling.** *The Journal of biological chemistry* 2005, **280(36):31537-31547.**
- 30 33. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC: **Dicer dependent**  
31 **microRNAs regulate gene expression and functions in human endothelial**  
32 **cells.** *Circulation research* 2007, **100(8):1164-1173.**
- 33 34. Owens GK, Kumar MS, Wamhoff BR: **Molecular regulation of vascular**  
34 **smooth muscle cell differentiation in development and disease.** *Physiological*  
35 *reviews* 2004, **84(3):767-801.**
- 36 35. Maegdefessel L, Rayner KJ, Leeper NJ: **MicroRNA regulation of vascular**  
37 **smooth muscle function and phenotype: early career committee contribution.**  
38 *Arteriosclerosis, thrombosis, and vascular biology* 2015, **35(1):2-6.**
- 39 36. Li Y, Yan L, Zhang W, Hu N, Chen W, Wang H, Kang M, Ou H: **MicroRNA-21**  
40 **inhibits platelet-derived growth factor-induced human aortic vascular**  
41 **smooth muscle cell proliferation and migration through targeting activator**  
42 **protein-1.** *American journal of translational research* 2014, **6(5):507-516.**
- 43 37. Davis BN, Hilyard AC, Lagna G, Hata A: **SMAD proteins control DROSHA-**  
44 **mediated microRNA maturation.** *Nature* 2008, **454(7200):56-61.**
- 45 38. Kinner A, Wu W, Staudt C, Iliakis G: **Gamma-H2AX in recognition and**  
46 **signaling of DNA double-strand breaks in the context of chromatin.** *Nucleic*  
47 *acids research* 2008, **36(17):5678-5694.**
- 48 39. Sheedy FJ, Moore KJ: **IL-1 signaling in atherosclerosis: sibling rivalry.** *Nature*  
49 *immunology* 2013, **14(10):1030-1032.**
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
40. Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U: **Regulation and involvement of matrix metalloproteinases in vascular diseases.** *Frontiers in bioscience (Landmark edition)* 2016, **21**:89-118.
41. Newby AC, Zaltsman AB: **Molecular mechanisms in intimal hyperplasia.** *The Journal of pathology* 2000, **190**(3):300-309.
42. Dangwal S, Bang C, Thum T: **Novel techniques and targets in cardiovascular microRNA research.** *Cardiovascular research* 2012, **93**(4):545-554.
43. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C: **Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models.** *Biochimica et biophysica acta* 2010, **1803**(1):3-19.
44. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB *et al*: **The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.** *Cell* 2001, **107**(6):789-800.
45. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM: **MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.** *Molecular and cellular biology* 2008, **28**(17):5369-5380.
46. Liu J, Chi D, Lu H, Zhang T, Yamakawa T: **Reversion-inducing-cysteine-rich protein with Kazal motif is involved in intimal hyperplasia in carotid arteries: a new insight in the prevention of restenosis after vascular angioplasty.** *Annals of vascular surgery* 2015, **29**(6):1293-1299.
47. Horita HN, Simpson PA, Ostriker A, Furgeson S, Van Putten V, Weiser-Evans MC, Nemenoff RA: **Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells.** *Arteriosclerosis, thrombosis, and vascular biology* 2011, **31**(12):2909-2919.
48. Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, Galuppo P, Kneitz S, Mayr M, Ertl G *et al*: **Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism.** *Circulation research* 2010, **107**(1):138-143.
49. Morioka Y, Monypenny J, Matsuzaki T, Shi S, Alexander DB, Kitayama H, Noda M: **The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts.** *Oncogene* 2009, **28**(11):1454-1464.
50. Ito I, Fixman ED, Asai K, Yoshida M, Gounni AS, Martin JG, Hamid Q: **Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2009, **39**(9):1370-1380.

## **Figure Legends**

**Figure 1: Overexpression of miR-21 alters SMC phenotype.** SV-SMC were transfected with 30nM premiR-21 and cultured for 72h. (A) Representative images of transfected SV-SMC and (B) quantification of spread cell area ( $n=7$ ,  $**P<0.01$ ). (C) Representative images of the F-actin cytoskeleton stained with rhodamine phalloidin. (D) After the 72h period, cells were placed in proliferation assays and direct cell counts taken after 4 days. Data is presented as a fold increase in cell number from day 0 ( $n=5$ ,  $**P<0.01$ ).

**Figure 2: miR-21 over-expression alters atherosclerosis-related gene expression** (A) Volcano plot of the RT2 Profiler Human Atherosclerosis PCR Microarray data. The difference in expression level (log 2 scale) is indicated on the x-axis and the y-axis indicates statistical significance (-log 10 scale). Values located above the horizontal dotted line indicate  $P < 0.05$ . Only genes that had  $\geq \pm 1.5$ -fold changes are labelled; genes upregulated by miR-21 over-expression are indicated in grey and those down-regulated are indicated in black ( $n=4$ ). The array data was validated using TaqMan® intron-spanning primers for (B) MMP-1 and (C) IL-1A (both  $n=6$ ). (D) Quantification of RECK mRNA in SV-SMC transfected with premiR-21 (or premiR-ve) for 72 h ( $n=8$ ). (E) Quantification of RECK protein in transfected cells after 8 days ( $n=5$ ,  $***P<0.001$ ). (F) Representative immunoblot with  $\alpha$ -tubulin as a loading control.  $***P<0.001$ ,  $**P<0.01$ ,  $*P<0.05$ , ns=not significant.

**Figure 3: PDGF induces miR-21 expression via AKT and ERK1/2, and inhibits MMP-1 and RECK1.** (A) SV-SMC were treated with increasing concentrations of

1  
2  
3 PDGF and miR-21 expression quantified after 24-72h ( $n=5$ ,  $**P<0.01$ ,  $*P<0.05$ , ns=not  
4 significant. (B) SV-SMC were treated with the PI3K inhibitor LY294002 (LY;  $10\mu\text{M}$ )  
5 and ERK1/2 inhibitor PD98059 (PD;  $30\mu\text{M}$ ) for 1 h prior to PDGF stimulation (20 min).  
6  
7 V refers to vehicle control. Representative Western blot demonstrating the efficacy of the  
8 inhibitors. (C) SV-SMC were treated with V, LY or PD for 1 h prior to the addition of  
9 PDGF. miR-21 expression was monitored 48 h later ( $n=5$ ,  $*P<0.05$ ). SV-SMC were  
10 treated with increasing concentrations of PDGF and the expression of (D) MMP-1 and  
11  
12 (E) RECK quantified after 24-72h ( $n=5$ ,  $***P<0.001$ ,  $**P<0.01$ ,  $*P<0.05$ , ns=not  
13 significant).

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25 **Figure 4: PDGF - miR-21 axis in SV-SMC.** PDGF-BB in the circulation signals  
26 through both AKT and ERK to up-regulate expression of miR-21. In turn, this inhibits  
27 MMP-1 and RECK1, and drives a phenotypic switch towards a synthetic SMC such as  
28  
29 the type prevalent in atherosclerosis and neointimal hyperplasia.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

FIGURE 1




Figure 1: Overexpression of miR-21 alters SMC phenotype

184x148mm (150 x 150 DPI)




Figure 2: miR-21 over-expression alters atherosclerosis-related gene expression

202x167mm (150 x 150 DPI)




Figure 3: PDGF induces miR-21 expression via AKT and ERK1/2, and inhibits MMP-1 and RECK1

238x132mm (150 x 150 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4: PDGF - miR-21 axis in SV-SMC

198x63mm (150 x 150 DPI)

Peer Review Only

**Table 1: Genes modulated by miR-21 overexpression in the Human Atherosclerosis****Microarray**

| Gene           | Log <sub>2</sub> fold change<br>(treated/control) | <i>P</i> value (ratio paired <i>t</i> -test) |
|----------------|---|--|
| Upregulated:   |   |  |
| <i>MMP1</i>    | 3.46  | 0.12   |
| <i>MMP3</i>    | 3.08  | 0.17   |
| <i>PPARG</i>   | 2.99  | 0.22   |
| <i>IL1R2</i>   | 2.96  | 0.19   |
| <i>ITGB2</i>   | 1.5   | 0.33   |
| Downregulated: |   |  |
| <i>IL5</i>     | -1.91   | 0.34   |
| <i>VWF</i>     | -2.06   | 0.41   |
| <i>BIRC3</i>   | -2.62   | 0.49   |
| <i>KDR</i>     | -3.62   | 0.18   |
| <i>IL1A</i>    | -5.32   | 0.02   |

Cells over-expressed miR-21 or the negative control, and RNA was subsequently analysed using the Human Atherosclerosis Microarray. Table shows genes with a log<sub>2</sub> fold change greater or equal to 1.5 upregulation or downregulation, and the related *P* value.